Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment providing unprecedented clinical benefits. However, many patients do not respond to ICIs as monotherapy or develop resistance. Combining ICI-based immunotherapy with chemotherapy is a promising strategy to inc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cells
Autors principals: Rossi, Alessandra, Lucarini, Valeria, Macchia, Iole, Sestili, Paola, Buccione, Carla, Donati, Simona, Ciccolella, Maria, Sistigu, Antonella, D’Urso, Maria Teresa, Pacca, Anna Maria, Cardarelli, Enrico, Mattei, Fabrizio, Proietti, Enrico, Schiavoni, Giovanna, Bracci, Laura
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226952/
https://ncbi.nlm.nih.gov/pubmed/32290265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9040940
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars